Cargando…
Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study
BACKGROUND: Health care workers (HCW) are among the highest risk groups for acquisition of COVID-19 because of occupational exposures. The WHIP COVID-19 Study aimed to evaluate the safety and efficacy of hydroxychloroquine (HCQ) as chemoprophylaxis for SARS-CoV-2 infection in this population. METHOD...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695310/ https://www.ncbi.nlm.nih.gov/pubmed/34954095 http://dx.doi.org/10.1016/j.ijid.2021.12.343 |
_version_ | 1784619548838723584 |
---|---|
author | McKinnon, John E. Wang, Dee Dee Zervos, Marcus Saval, Matt Marshall-Nightengale, Laurie Kilgore, Paul Pabla, Pardeep Szandzik, Ed Maksimowicz-McKinnon, Kathleen O'Neill, William W. |
author_facet | McKinnon, John E. Wang, Dee Dee Zervos, Marcus Saval, Matt Marshall-Nightengale, Laurie Kilgore, Paul Pabla, Pardeep Szandzik, Ed Maksimowicz-McKinnon, Kathleen O'Neill, William W. |
author_sort | McKinnon, John E. |
collection | PubMed |
description | BACKGROUND: Health care workers (HCW) are among the highest risk groups for acquisition of COVID-19 because of occupational exposures. The WHIP COVID-19 Study aimed to evaluate the safety and efficacy of hydroxychloroquine (HCQ) as chemoprophylaxis for SARS-CoV-2 infection in this population. METHODS: HCW, first responders, and other occupationally high-risk participants were enrolled in a randomized, placebo-controlled clinical study of HCQ from April to October 2020. The trial compared daily versus weekly HCQ with placebo and with a prospective cohort on HCQ for autoimmune diseases. Participants were followed for 8 weeks. Serology or a positive polymerase chain reaction test was used to determine laboratory confirmed clinical cases. RESULTS: A total of 624 participants were randomized to placebo (n = 200), weekly HCQ (n = 201), daily HCQ (n = 197). For the primary safety end point, 279 (44.7%) participants experienced adverse event (AE) level II or lower (total AEs n = 589), similar rates in all randomized groups (P = .188) with no hospitalizations or interventions required. Only 4 laboratory confirmed COVID-19 cases occurred, with 2 in the placebo arm and one in each HCQ randomized arm. CONCLUSIONS: This randomized placebo-controlled trial was able to demonstrate the safety of HCQ outpatient chemoprophylaxis in high-risk groups against COVID-19. Future studies of chemoprophylaxis for SARS-CoV-2 are needed as the epidemic continues worldwide. |
format | Online Article Text |
id | pubmed-8695310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86953102021-12-23 Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study McKinnon, John E. Wang, Dee Dee Zervos, Marcus Saval, Matt Marshall-Nightengale, Laurie Kilgore, Paul Pabla, Pardeep Szandzik, Ed Maksimowicz-McKinnon, Kathleen O'Neill, William W. Int J Infect Dis Article BACKGROUND: Health care workers (HCW) are among the highest risk groups for acquisition of COVID-19 because of occupational exposures. The WHIP COVID-19 Study aimed to evaluate the safety and efficacy of hydroxychloroquine (HCQ) as chemoprophylaxis for SARS-CoV-2 infection in this population. METHODS: HCW, first responders, and other occupationally high-risk participants were enrolled in a randomized, placebo-controlled clinical study of HCQ from April to October 2020. The trial compared daily versus weekly HCQ with placebo and with a prospective cohort on HCQ for autoimmune diseases. Participants were followed for 8 weeks. Serology or a positive polymerase chain reaction test was used to determine laboratory confirmed clinical cases. RESULTS: A total of 624 participants were randomized to placebo (n = 200), weekly HCQ (n = 201), daily HCQ (n = 197). For the primary safety end point, 279 (44.7%) participants experienced adverse event (AE) level II or lower (total AEs n = 589), similar rates in all randomized groups (P = .188) with no hospitalizations or interventions required. Only 4 laboratory confirmed COVID-19 cases occurred, with 2 in the placebo arm and one in each HCQ randomized arm. CONCLUSIONS: This randomized placebo-controlled trial was able to demonstrate the safety of HCQ outpatient chemoprophylaxis in high-risk groups against COVID-19. Future studies of chemoprophylaxis for SARS-CoV-2 are needed as the epidemic continues worldwide. Elsevier 2022-03 /pmc/articles/PMC8695310/ /pubmed/34954095 http://dx.doi.org/10.1016/j.ijid.2021.12.343 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article McKinnon, John E. Wang, Dee Dee Zervos, Marcus Saval, Matt Marshall-Nightengale, Laurie Kilgore, Paul Pabla, Pardeep Szandzik, Ed Maksimowicz-McKinnon, Kathleen O'Neill, William W. Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study |
title | Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study |
title_full | Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study |
title_fullStr | Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study |
title_full_unstemmed | Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study |
title_short | Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study |
title_sort | safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of covid-19: whip covid-19 study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695310/ https://www.ncbi.nlm.nih.gov/pubmed/34954095 http://dx.doi.org/10.1016/j.ijid.2021.12.343 |
work_keys_str_mv | AT mckinnonjohne safetyandtolerabilityofhydroxychloroquineinhealthcareworkersandfirstrespondersforthepreventionofcovid19whipcovid19study AT wangdeedee safetyandtolerabilityofhydroxychloroquineinhealthcareworkersandfirstrespondersforthepreventionofcovid19whipcovid19study AT zervosmarcus safetyandtolerabilityofhydroxychloroquineinhealthcareworkersandfirstrespondersforthepreventionofcovid19whipcovid19study AT savalmatt safetyandtolerabilityofhydroxychloroquineinhealthcareworkersandfirstrespondersforthepreventionofcovid19whipcovid19study AT marshallnightengalelaurie safetyandtolerabilityofhydroxychloroquineinhealthcareworkersandfirstrespondersforthepreventionofcovid19whipcovid19study AT kilgorepaul safetyandtolerabilityofhydroxychloroquineinhealthcareworkersandfirstrespondersforthepreventionofcovid19whipcovid19study AT pablapardeep safetyandtolerabilityofhydroxychloroquineinhealthcareworkersandfirstrespondersforthepreventionofcovid19whipcovid19study AT szandziked safetyandtolerabilityofhydroxychloroquineinhealthcareworkersandfirstrespondersforthepreventionofcovid19whipcovid19study AT maksimowiczmckinnonkathleen safetyandtolerabilityofhydroxychloroquineinhealthcareworkersandfirstrespondersforthepreventionofcovid19whipcovid19study AT oneillwilliamw safetyandtolerabilityofhydroxychloroquineinhealthcareworkersandfirstrespondersforthepreventionofcovid19whipcovid19study |